{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["25(1)"],"submitter":["Sreenath ND"],"pubmed_abstract":["<h4>Introduction</h4>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as Palbociclib and Ribociclib, have significantly improved outcomes for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Although clinical trials have established the efficacy of these agents globally, real-world data from India is limited. This study compares the clinical effectiveness and safety profiles of Palbociclib and Ribociclib in a cohort of Indian patients.<h4>Materials and methods</h4>This prospective study included 60 patients with metastatic HR+/HER2- breast cancer treated at Army hospitals and research centers in India between 2020 and 2023. Progression-free survival (PFS), overall survival (OS), and safety profiles were analyzed to assess the real-world perfor"],"journal":["BMC cancer"],"pagination":["1337"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12362974"],"repository":["biostudies-literature"],"pubmed_title":["A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort."],"pmcid":["PMC12362974"],"pubmed_authors":["Mulajker D","Bhuva D","Sreenath ND","Kaushik MR","Rathore A","Kumar M","Pandalanghat S","Kapoor A","Nair R","Govind R"],"additional_accession":[]},"is_claimable":false,"name":"A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort.","description":"<h4>Introduction</h4>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as Palbociclib and Ribociclib, have significantly improved outcomes for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Although clinical trials have established the efficacy of these agents globally, real-world data from India is limited. This study compares the clinical effectiveness and safety profiles of Palbociclib and Ribociclib in a cohort of Indian patients.<h4>Materials and methods</h4>This prospective study included 60 patients with metastatic HR+/HER2- breast cancer treated at Army hospitals and research centers in India between 2020 and 2023. Progression-free survival (PFS), overall survival (OS), and safety profiles were analyzed to assess the real-world perfor","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-02T03:49:31.978Z","creation":"2026-04-07T17:36:12.905Z"},"accession":"S-EPMC12362974","cross_references":{"pubmed":["40826034"],"doi":["10.1186/s12885-025-14270-1"]}}